D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain

Inclusion Criteria: * Patients will be at least 18 years of age. * Patients will be experiencing moderate to severe peripheral neuropathic pain * Patients may be on chronic adjuvant pain medications such as antidepressants but must be on stable doses for at least one week prior to admission. * Patients may be taking concurrent opioids but they must be willing to allow us to monitor their opioid use while on the trial. * Patients must have chronic peripheral neuropathic pain will be defined as pain of 3 or more months duration which began in association with chemotherapy. * Patient's will have bilateral peripheral neuropathic pain symptoms primarily involving the feet * Patients must have breast cancer (any stage) * Patients must be able to read and speak English and provide informed consent. * Patients may be receiving chemotherapy as long as the agents are not known to cause a peripheral neuropathy. * Patients must have an ECOG Performance Status \< 3 and be able to attend the physician study visits * Patients must not concurrently use gabapentin or pregabalin or must be willing to wean off their anti-convulsant medications prior to starting the trial. * Patients may have diabetes mellitus (type 1 or 2) as long as there is no preexisting neuropathy. Exclusion criteria: * Patients will not have secondary cause of neuropathic pain including: HIV/AIDS,traumatic injury, or a personal history of non chemotherapy-induced neuropathy. * Patients will not have a history of major depression or severe anxiety. * Women of childbearing age will agree to take measures to prevent pregnancy and will not breast-feed while on the study medication. Women who are currently pregnant will not be invited to participate in this study. * Patients will not have a history of seizures. * Patients cannot be currently receiving antibiotic therapy for tuberculosis (e.g. isoniazid).